Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 6/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030573 | 0.81 | DAO (0.49) | NQO2KDM4EMEN1POLBMAPT | |
| SCHEMBL7033735 | 0.81 | KDM4E (0.41) | NQO2KDM4EMEN1POLBMAPT | |
| SCHEMBL7029217 | 0.81 | KDM4E (0.41) | NQO2KDM4EMEN1POLBMAPT | |
| SCHEMBL7040483 | 0.79 | CYP2A6 (0.44) | KDM4EMEN1MAPTKMT2ALMNA | |
| SCHEMBL28325027 | 0.78 | KDM4E (0.62) | NQO2KDM4EMEN1POLBMAPT | |
| SCHEMBL7031280 | 0.78 | PARP1 (0.41) | NQO2KDM4EMEN1POLBMAPT | |
| SCHEMBL7032421 | 0.78 | KDM4E (0.41) | NQO2KDM4EMEN1POLBMAPT | |
| SCHEMBL7027327 | 0.78 | KDM4E (0.41) | NQO2KDM4EMEN1POLBMAPT | |
| SCHEMBL7030040 | 0.78 | KDM4E (0.41) | NQO2KDM4EMEN1POLBMAPT | |
| SCHEMBL7030828 | 0.78 | KDM4E (0.58) | NQO2KDM4EPOLBALDH1A1TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| CN-119968360-A | Quinazoline compound and application thereof | 赛诺哈勃药业（成都）有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024131938-A1 | QUINAZOLINE COMPOUND AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| WO-2023143135-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116514728-A | Quinazoline derivative and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3078660-B1 | NOVEL QUINAZOLINE DERIVATIVE | MYCHUNTER THERAPEUTICS INC (JP) | 2022-07-13 | — | — | EP | disclosed |
| US-9682961-B2 | Quinazoline derivative | CARNA BIOSCIENCES, INC. (JP) | 2017-06-20 | — | — | US | disclosed |
| WO-1997020821-A1 | HETEROARYL DERIVATIVES | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| EP-0775697-A1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-05-28 | — | — | EP | disclosed |
| EP-0760819-A1 | TRICYCLIC DICARBONYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995032205-A1 | TRICYCLIC DICARBONYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1995-11-30 | — | — | WO | disclosed |
| US-5064833-A | Substituted quinazoline derivatives for use in gastrointestinal diseases | SMITHKLINE BEECHAM INTERCREDIT B.V. (GB) | 1991-11-12 | — | — | US | disclosed |
| EP-0322133-B1 | QUINAZOLINE DERIVATIVES | SmithKline Beecham Intercredit B.V. (NL) | 1991-05-22 | — | — | EP | disclosed |
| EP-0322133-A1 | Quinazoline derivatives | SmithKline Beecham Intercredit B.V. (NL) | 1989-06-28 | — | — | EP | disclosed |
| WO-1989005297-A1 | COMPOUNDS | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | NQO2 500/4885KDM4E 2328/4885MEN1 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.